{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:55:12Z","timestamp":1787316912157,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.bbmt.2016.05.014","type":"journal-article","created":{"date-parts":[[2016,5,29]],"date-time":"2016-05-29T10:16:22Z","timestamp":1464516982000},"page":"1646-1653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"22","author":[{"given":"Evelyn","family":"Rustia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Violago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhezhen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc D.","family":"Foca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine M.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sosna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Garvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3867-9066","authenticated-orcid":false,"given":"Prakash","family":"Satwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.05.014_bib1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cct.2015.06.011","article-title":"Making strides and meeting challenges in pediatric allogeneic hematopoietic cell transplantation clinical trials in the United States: Past, present and future","volume":"45","author":"Satwani","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.bbmt.2016.05.014_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.bmt.1705550","article-title":"Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation","volume":"39","author":"Miano","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.05.014_bib3","doi-asserted-by":"crossref","first-page":"E451","DOI":"10.1188\/12.ONF.E451-E458","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation in pediatric patients and subsequent supportive care","volume":"39","author":"Barrell","year":"2012","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.bbmt.2016.05.014_bib4","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.05.014_bib5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2010.32.5001","article-title":"Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?","volume":"29","author":"Horan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.05.014_bib6","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood-2010-01-261958","article-title":"Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors","volume":"116","author":"Shaw","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.05.014_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1705249","article-title":"Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning","volume":"37","author":"Kline","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.05.014_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/bmt.2012.221","article-title":"Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients","volume":"48","author":"Hiwarkar","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.05.014_bib9","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.05.014_bib10","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/00007890-199811270-00012","article-title":"Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients","volume":"66","author":"Ljungman","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2016.05.014_bib11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.V97.4.867","article-title":"Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes","volume":"97","author":"Nichols","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.05.014_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.05.014_bib13","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/cid\/cit391","volume":"57","author":"Styczynski","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2016.05.014_bib14","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.bbmt.2010.04.008","article-title":"Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Schonberger","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.05.014_bib15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2016.05.014_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1399-3046.2011.01634.x","article-title":"Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation","volume":"16","author":"Bordon","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2016.05.014_bib17","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution","volume":"99","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.05.014_bib18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.bbmt.2009.10.007","article-title":"An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients","volume":"16","author":"Bhatia","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.05.014_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.bbmt.2014.11.679","article-title":"Efficacy of tacrolimus\/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation","volume":"21","author":"Offer","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.05.014_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2016.05.014_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/pbc.21043","article-title":"A\u00a0pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients","volume":"49","author":"Shereck","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2016.05.014_bib22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbmt.2013.11.009","article-title":"Patient, virus, and treatment-related risk factors in pediatric adenovirus infection after stem cell transplantation: results of a routine monitoring program","volume":"20","author":"Mynarek","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.05.014_bib23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2016.05.014_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.bmt.1703798","article-title":"Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"31","author":"Ljungman","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.05.014_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/tid.12022","article-title":"European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011)","volume":"14","author":"Matthes-Martin","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2016.05.014_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jim.2014.05.011","article-title":"Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches","volume":"408","author":"Tischer","year":"2014","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.bbmt.2016.05.014_bib27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-3046.2009.01226.x","article-title":"Multiple viral infections post-hematopoietic stem cell transplantation are linked to the appearance of chronic GVHD among pediatric recipients of allogeneic grafts","volume":"14","author":"Olkinuora","year":"2010","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2016.05.014_bib28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bbmt.2016.05.014_bib29","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.05.014_bib30","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2016.05.014_bib31","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.05.014_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/14653249.2011.636963","article-title":"Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant","volume":"14","author":"Sili","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2016.05.014_bib33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/cid\/cis900","article-title":"An international multicenter performance analysis of cytomegalovirus load tests","volume":"56","author":"Hirsch","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2016.05.014_bib34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.hemonc.2013.08.003","article-title":"Pre-emptive virology screening in the pediatric hematopoietic stem cell transplant population: a cost effectiveness analysis","volume":"6","author":"Evers","year":"2013","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.bbmt.2016.05.014_bib35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcyt.2013.11.010","article-title":"The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care","volume":"16","author":"Saglio","year":"2014","journal-title":"Cytotherapy"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116300866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116300866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:56:49Z","timestamp":1761058609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116300866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1083879116300866"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.05.014","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}